Department of Molecular Pharmacology & Physiology, College of Medicine, University of South Florida, Tampa, Florida, USA.
Department of Otolarynggology-Head and Neck Surgery, Cheeloo College of Medicine, Shandong University, Jinan, China.
Kidney Int. 2022 Mar;101(3):541-550. doi: 10.1016/j.kint.2021.10.037. Epub 2021 Nov 26.
An increase of glomerular filtration rate (GFR) is a common observation in early diabetes and is considered a key risk factor for subsequent kidney injury. However, the mechanisms underlying diabetic hyperfiltration have not been fully clarified. Here, we tested the hypothesis that macula densa neuronal nitric oxide synthase (NOS1) is upregulated via sodium glucose cotransporter type 1 (SGLT1) in diabetes, which then inhibits tubuloglomerular feedback (TGF) promoting glomerular hyperfiltration. Therefore, we examined changes in cortical NOS1 expression and phosphorylation, nitric oxide production in the macula densa, TGF response, and GFR during the early stage of insulin-deficient (Akita) diabetes in wild-type and macula densa-specific NOS1 knockout mice. A set of sophisticated techniques including microperfusion of juxtaglomerular apparatus in vitro, micropuncture of kidney tubules in vivo, and clearance kinetics of plasma fluorescent-sinistrin were employed. Complementary studies tested the role of SGLT1 in SGLT1 knockout mice and explored NOS1 expression and phosphorylation in kidney biopsies of cadaveric donors. Diabetic mice had upregulated macula densa NOS1, inhibited TGF and elevated GFR. Macula densa-selective NOS1 knockout attenuated the diabetes-induced TGF inhibition and GFR elevation. Additionally, deletion of SGLT1 prevented the upregulation of macula densa NOS1 and attenuated inhibition of TGF in diabetic mice. Furthermore, the expression and phosphorylation levels of NOS1 were increased in cadaveric kidneys of diabetics and positively correlated with blood glucose as well as estimated GFR in the donors. Thus, our findings demonstrate that the macula densa SGLT1-NOS1-TGF pathway plays a crucial role in the control of GFR in diabetes.
肾小球滤过率(GFR)升高是糖尿病早期的常见现象,被认为是随后发生肾损伤的关键危险因素。然而,糖尿病高滤过的机制尚未完全阐明。在这里,我们检验了这样一个假设,即致密斑神经元型一氧化氮合酶(NOS1)通过糖尿病中的葡萄糖钠协同转运蛋白 1(SGLT1)上调,从而抑制管球反馈(TGF),促进肾小球高滤过。因此,我们在野生型和致密斑特异性 NOS1 敲除小鼠的胰岛素缺乏型(Akita)糖尿病早期,检查了皮质 NOS1 表达和磷酸化、致密斑中一氧化氮产生、TGF 反应和 GFR 的变化。我们采用了一系列复杂的技术,包括体外肾小球旁器微灌流、体内肾小管微穿刺和血浆荧光丝氨酸清除动力学。补充研究测试了 SGLT1 在 SGLT1 敲除小鼠中的作用,并探讨了尸体供体肾活检中的 NOS1 表达和磷酸化。糖尿病小鼠的致密斑 NOS1 上调,TGF 抑制和 GFR 升高。致密斑选择性 NOS1 敲除减轻了糖尿病诱导的 TGF 抑制和 GFR 升高。此外,SGLT1 的缺失可防止糖尿病小鼠致密斑 NOS1 的上调,并减轻 TGF 的抑制。此外,糖尿病患者尸体供体的肾脏中 NOS1 的表达和磷酸化水平增加,并且与供体的血糖和估计的 GFR 呈正相关。因此,我们的研究结果表明,致密斑 SGLT1-NOS1-TGF 途径在糖尿病中 GFR 的控制中起关键作用。